Xenon Reports Positive Phase 1 Results for Pain Drugs XEN1701 and XEN1120

• Xenon Pharmaceuticals plans Phase 2 acute pain studies of XEN1701 and XEN1120 in the first half of 2027 following positive Phase 1 results.
• XEN1701 achieved modeled NaV1.7 receptor occupancy above 75% in peripheral and central nervous systems, without consistent autonomic cardiovascular effects.
• XEN1120 exceeded predicted effective exposures from animal models; modeling supported sustained target concentrations with maintenance dosing.
• Both drugs were generally well tolerated, with no treatment-related, dose-limiting adverse events or adverse events leading to discontinuation.
• A compound comparable to XEN1701 reduced evoked pain by approximately 85%-100% at the two highest doses in monkeys, without meaningful cardiovascular changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290830PRIMZONEFULLFEED9855934) on October 29, 2026, and is solely responsible for the information contained therein.